Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Radiant Pharmaceuticals Limited (RPL), one of the top healthcare solution providers in Bangladesh, is set to buy a majority ...
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug ...
The U.S. Court of Appeals has reportedly ruled against Novartis (NVS) in its bid to prevent the U.S. launch of a generic ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) on December 3 and set a price target of ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...